2024
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do A, Zahrawi F, Mehal W. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nature Reviews Drug Discovery 2024, 24: 171-189. PMID: 39609545, DOI: 10.1038/s41573-024-01084-2.Peer-Reviewed Original ResearchSide effect profileTrial end pointsCombination of therapeuticsReverse many aspectsFatty acid synthase inhibitorGenetic susceptibility factorsPlacebo responseEffect profileFibrosis reversalTreated patientsClinical studiesLiver inflammationSynthase inhibitorLiver diseaseTherapeutic approachesClinical useEnd pointsSteatotic liver diseaseTherapeutic landscapeMetabolic environmentHepatocyte deathSusceptibility factorsChronic overnutritionGlobal epidemicLiver
2023
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution
Santinelli E, Pascale M, Xie Z, Badar T, Stahl M, Bewersdorf J, Gurnari C, Zeidan A. Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution. Blood Reviews 2023, 62: 101130. PMID: 37679263, DOI: 10.1016/j.blre.2023.101130.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaMyeloid malignanciesLeukemia cell survivalBcl-2 signalingPro-apoptotic agentsClinical studiesMyeloid leukemiaMyeloid neoplasmsTherapeutic revolutionMolecular alterationsMyeloid neoplasiaTherapeutic landscapeSpecific drugsApoptosis dysregulationSynergistic efficacyNew drugsMechanism of apoptosisDrugsMalignancyCombination strategiesCell survivalAttractive targetApoptotic pathwayTreatmentApoptosisPediatric Neurogastroenterology and Motility Disorders What Role Does Endoscopy Play?
Khlevner J, Patel D, Rodriguez L. Pediatric Neurogastroenterology and Motility Disorders What Role Does Endoscopy Play? Gastrointestinal Endoscopy Clinics Of North America 2023, 33: 379-399. PMID: 36948752, DOI: 10.1016/j.giec.2022.10.004.Peer-Reviewed Original ResearchConceptsPaediatric neurogastroenterologyMotility disordersOral endoscopic myotomyTherapeutic gastrointestinal endoscopyIncisional therapySmall bowelEndoscopic myotomyAnorectal disordersGastrointestinal endoscopyDiagnostic endoscopyFunctional lumenAxis interactionTherapeutic landscapeNovel modalityDisordersNeurogastroenterologyEndoscopyBowelMyotomyEsophagealColonicTherapyAcute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony S, Stahl M, Stone R. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management. American Journal Of Hematology 2023, 98: 502-526. PMID: 36594187, DOI: 10.1002/ajh.26822.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaTherapeutic landscape of acute myeloid leukemiaPatient acute myeloid leukemiaInternational consensus classificationMalignant myeloid cellsStem cell cancerTherapeutic decision makingMarrow stem cellsCell cancerTherapeutic algorithmMyeloid leukemiaMyeloid cellsRisk stratificationWHO systemTherapeutic complexMutation profilesDisease characteristicsMolecular findingsConsensus classificationTherapeutic landscapeStem cellsRisk classificationLeukemiaIntegration of molecular analysisTrial results
2022
Predictive Biomarkers in the Management of Bladder Cancer: Perspectives in an Evolving Therapeutic Landscape
Hensley P, Lobo N, Bree K, Tan W, Gontero P, Williams S, Guo C, Giannarini G, Dyrskjøt L, Kamat A. Predictive Biomarkers in the Management of Bladder Cancer: Perspectives in an Evolving Therapeutic Landscape. Société Internationale D’Urologie Journal 2022, 3: 245-257. DOI: 10.48083/rvzv1144.Peer-Reviewed Original ResearchPredictive biomarkersBladder cancerPredictive biomarkers of therapeutic responseBiomarkers of therapeutic responseManagement of bladder cancerBladder preservation strategiesSequence of therapyMuscle-invasive BCNon-muscle-invasiveEvolving therapeutic landscapeTherapeutic mechanism of actionAdvanced disease stateLikelihood of responseSerum-based biomarkersSystemic therapyTumor gradeTargeted therapyMechanism of actionTherapeutic responseHeterogeneous diseaseUrine-basedPrognostic capacityTherapeutic strategiesTherapeutic landscapeTherapyAn Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies
Yi JS, Perla S, Bennett AM. An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies. Cardiovascular Drugs And Therapy 2022, 37: 1193-1204. PMID: 35156148, PMCID: PMC11726350, DOI: 10.1007/s10557-022-07324-0.Peer-Reviewed Original ResearchConceptsRas-MAPK pathwayRAS/mitogen-activated protein kinase (MAPK) pathwayMitogen-activated protein kinase pathwayPost-developmental processesProtein kinase pathwayHypertrophic cardiomyopathyKinase pathwayRASopathy patientsDevelopmental diseasesNoonan syndromeTreatment of HCMRASopathiesCardiofaciocutaneous syndromePathwayNeurofibromatosis type 1Cardiovascular defectsValvular abnormalitiesCardiovascular manifestationsHeart diseaseClinical informationCostello syndromeCongenital heartMultiple lentiginesTherapeutic landscapeAntineoplastic drugs
2020
Evolving therapies for lower-risk myelodysplastic syndromes
Bewersdorf JP, Zeidan AM. Evolving therapies for lower-risk myelodysplastic syndromes. Annals Of Hematology 2020, 99: 677-692. PMID: 32078008, DOI: 10.1007/s00277-020-03963-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnemiaBlood TransfusionChelation TherapyClinical Trials as TopicCri-du-Chat SyndromeDrugs, InvestigationalForecastingHematinicsHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsIron OverloadLenalidomideMolecular Targeted TherapyMulticenter Studies as TopicMyelodysplastic SyndromesPrecision MedicinePrognosisRisk AssessmentSeverity of Illness IndexConceptsInternational Prognostic Scoring SystemLow-risk MDS patientsMyelodysplastic syndromeMDS patientsLower-risk myelodysplastic syndromesPrognostic scoring systemRisk stratification toolAdvanced clinical testingSymptomatic anemiaStratification toolHematologic malignanciesCurrent treatmentTherapeutic approachesNew agentsNew drug approvalsTherapeutic conceptsClinical developmentPatientsClinical testingMolecular pathogenesisScoring systemTherapeutic landscapePromising agentDrug approvalGenetic features
2019
The changing therapeutic landscape of head and neck cancer
Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nature Reviews Clinical Oncology 2019, 16: 669-683. PMID: 31189965, DOI: 10.1038/s41571-019-0227-z.Peer-Reviewed Original ResearchConceptsNeck cancerTherapeutic landscapeNeck squamous cell carcinomaFirst immunotherapeutic agentHuman papillomavirus infectionNon-surgical therapyUpper aerodigestive tractSquamous cell carcinomaDifferent treatment modalitiesPapillomavirus infectionAerodigestive tractImmunotherapeutic agentsCell carcinomaTreatment modalitiesClinical trialsOral cavitySalivary glandsWidespread testingHNSCCDevelopment of strategiesCancerCurrent eraHeadOropharynxPatientsImmune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets
Stahl M, Goldberg A. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. Current Oncology Reports 2019, 21: 37. PMID: 30904967, DOI: 10.1007/s11912-019-0781-7.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaImmune checkpoint inhibitionImmune checkpoint inhibitorsCheckpoint inhibitorsCheckpoint inhibitionHypomethylating agentsMyeloid leukemiaCombination of immune checkpoint inhibitionSuccess of immune checkpoint inhibitionClinical trialsEarly-phase clinical trialsCheckpoint inhibitor monotherapyMultiple clinical trialsCheckpoint therapyImmune checkpointsInhibitor monotherapyStandard therapySolid malignanciesImmune targetsTherapeutic efficacyClinical activityTherapeutic landscapeLeukemiaTherapeutic targetLeukemia cells
2012
New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
Nicholas J, Morgan-Followell B, Pitt D, Racke MK, Boster A. New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. Journal Of Central Nervous System Disease 2012, 4: jcnsd.s6692. PMID: 23650470, PMCID: PMC3619700, DOI: 10.4137/jcnsd.s6692.Peer-Reviewed Original ResearchMultiple sclerosisRelapsing-remitting multiple sclerosisKey clinical trialsDisease-modifying therapiesMonoclonal antibody therapyIFN β-1aIFN-β-1bMS includingAvailable efficacyOral agentsGlatiramer acetateTreatment algorithmAntibody therapyClinical trialsPromising therapySafety dataNew therapiesTherapyNew FDATherapeutic landscapeActive investigationNatalizumabFingolimodSclerosisFDA
2011
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
Boster A, Bartoszek MP, O’Connell C, Pitt D, Racke M. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis. Therapeutic Advances In Neurological Disorders 2011, 4: 319-332. PMID: 22010043, PMCID: PMC3187678, DOI: 10.1177/1756285611422108.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply